4-(3-tert-butoxy-3-oxopropyl)benzoic acid | 953435-23-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(3-tert-butoxy-3-oxopropyl)benzoic acid
• 英文别名: 4-(2-(tert-Butoxycarbonyl)ethyl)benzoic acid；4-[3-[(2-methylpropan-2-yl)oxy]-3-oxopropyl]benzoic acid
• CAS: 953435-23-9
• 化学式: C₁₄H₁₈O₄
• 分子量: 250.295
• InChiKey: SSNDNMLARUSPEQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• N- (2 -AMINOPHENYL) BENZAMIDE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS
  申请人：Grigg Ronald Ernest

  公开号：US20140135327A1

  公开（公告）日：2014-05-15

  This invention relates to the discovery of novel compounds, or pharmaceutically acceptable salts thereof, which possess HDAC inhibitory activity. In particular, the compounds of the invention demonstrate selectivity towards Class I HDAC enzymes, and are accordingly expected to be useful for their anti-proliferative activity and in methods of treatment of the human or animal body, for example in preventing or inhibiting tumour growth and metastasis in cancers. The invention also relates to processes for the manufacture of the compounds defined herein, or pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-proliferative effect in a warm-blooded animal such as man.

  该发明涉及新化合物的发现，或其药用盐，具有HDAC抑制活性。具体而言，该发明的化合物表现出对I类HDAC酶的选择性，并因此预计对其抗增殖活性以及在人体或动物体内的治疗方法中具有用处，例如在预防或抑制癌症中的肿瘤生长和转移。该发明还涉及制备本文所定义的化合物或其药用盐的工艺，含有这些化合物的药物组合物以及它们在制造用于在温血动物（如人）中产生抗增殖效应的药物的生产中的用途。
• Factor XIa Inhibitors
  申请人：Mertz Eric

  公开号：US20160229839A1

  公开（公告）日：2016-08-11

  The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

  本发明提供了一种式（I）的化合物以及包含一种或多种所述化合物的药物组合物，以及使用这些化合物用于治疗或预防血栓、栓塞、高凝血状态或纤维变化的方法。这些化合物是选择性因子XIa抑制剂或因子XIa和血浆激酶双重抑制剂。
• ACTIVATED CYTOTOXIC COMPOUNDS FOR ATTACHMENT TO TARGETING MOLECULES FOR THE TREATMENT OF MAMMALIAN DISEASE CONDITIONS
  申请人：Fegley Glenn

  公开号：US20100022615A1

  公开（公告）日：2010-01-28

  Activated cytotoxic compounds are described for attachment to targeting molecules for the treatment of a mammalian disease condition which comprise, an activator, a spacer linker, a linker (e.g., self-immolative), and a cytotoxic drug selected from the group consisting of AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES, AMINO-AND-HYDROXY SUBSTITUTED STYRYLSULFONANILIDES, and SUBSTITUTED PHENOXY- AND PHENYLTHIO-STYRYLSULFONE DERIVATIVES. Activated cytotoxic compound attached to a targeting molecule are described wherein the targeting molecule is selected from the group consisting essentially of an antibody, a receptor, a ligand, a cytokine, a hormone, and a signal transduction molecule. The invention is further directed to a method of treatment of disease conditions.

  本发明涉及一种激活的细胞毒性化合物，用于附着于靶向分子治疗哺乳动物疾病状况，包括激活剂、间隔连接剂、连接剂（例如自解性连接剂）和从AMINO-SUBSTITUTED（E）-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES、AMINO-AND-HYDROXY SUBSTITUTED STYRYLSULFONANILIDES和SUBSTITUTED PHENOXY-AND PHENYLTHIO-STYRYLSULFONE DERIVATIVES组成的细胞毒性药物。本发明还涉及附着于靶向分子的激活的细胞毒性化合物，其中靶向分子从抗体、受体、配体、细胞因子、激素和信号转导分子等组成的群体中选择。本发明进一步涉及一种治疗疾病状况的方法。
• Inhibitors of Histone Deacetylase
  申请人：Moradei Oscar

  公开号：US20080132503A1

  公开（公告）日：2008-06-05

  The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  本发明涉及抑制组蛋白去乙酰化酶。本发明提供了抑制组蛋白去乙酰化酶酶活性的化合物和方法。本发明还提供了治疗细胞增殖性疾病和病症的组合物和方法。
• HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
  申请人：Chuaqui Claudio

  公开号：US20120040951A1

  公开（公告）日：2012-02-16

  The present invention provides compounds of formula (I) useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.

  本发明提供了式（I）的化合物，可用作Raf蛋白激酶的抑制剂。本发明还提供了其组合物以及治疗Raf介导疾病的方法。